Login to Your Account



'A strong fit strategically'

Solosec solo no longer: Lupin snags Symbiomix for $150M

By Marie Powers
News Editor

Thursday, October 12, 2017

Symbiomix Therapeutics LLC, which saw its single asset, Solosec (secnidazole, previously SYM-1219), approved by the FDA last month to treat bacterial vaginosis (BV), agreed to a buyout by Lupin Inc., the U.S. subsidiary of Mumbai-based Lupin Ltd., for $150 million, including $50 million up front. Lupin, which has a global presence but focuses largely on generics, earlier this year took an option to acquire privately held Symbiomix, which specialized in therapies to treat gynecologic infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription